Welcome to our dedicated page for REGENTIS BIOMATERIALS LTD. SEC filings (Ticker: RGNT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Regentis Biomaterials Ltd. (RGNT) SEC filings page on Stock Titan provides access to the company’s U.S. regulatory disclosures, including current reports on Form 6-K and registration materials related to its NYSE American listing. As a foreign private issuer, Regentis uses Form 6-K to furnish press releases and other information that it makes public in its home market or files with other regulators.
Recent 6-K filings incorporate press releases on clinical and scientific developments for GelrinC, the company’s lead cell-free, off-the-shelf hydrogel implant for focal articular knee cartilage injuries. For example, a 6-K furnishes the press release titled “Regentis’ GelrinC Establishes Long-Term Durability of Cartilage Repair Through Quantitative MOCART Evaluation,” summarizing Phase II data published in the journal Cartilage and describing MRI-based MOCART scores at 24 months. Another 6-K includes the press release “Regentis Biomaterials Granted New U.S. Patent for its Off-the-Shelf Regenerative Cartilage Repair Product GelrinC,” outlining patent protection for the liquid, ready-to-use formulation and solvent-free production processes.
Filings also cover corporate and governance events, such as changes in executive leadership, and provide formal notice of these developments under the Exchange Act. In addition, the company’s registration statement on Form F-1 and related documents detail its initial public offering of ordinary shares and listing on the NYSE American under the symbol RGNT.
On Stock Titan, these SEC documents are updated as they are made available through EDGAR. AI-powered tools can help readers quickly understand the key points in each filing, such as clinical endpoints, regulatory milestones, intellectual property disclosures, and changes in management, without needing to parse every page manually.
Regentis Biomaterials Ltd. (RGNT) has filed a post-effective amendment to its Form F-1 to update a resale registration for up to 3,807,143 ordinary shares. The shares may be sold from time to time by selling shareholders and consist of 1,844,543 shares issued in a June 2026 private placement and 1,962,600 shares issuable upon exercise of related warrants, including pre-funded, ordinary and placement agent warrants. Regentis will not receive proceeds from any resale of these shares, but could receive approximately $8.21 million if all registered warrants are exercised for cash. Ordinary shares outstanding were 7,023,921 as of September 17, 2026; this is a baseline figure, not the amount being offered. The amendment also refreshes financial and business information, highlighting GelrinC, the company’s CE-marked hydrogel implant for knee cartilage repair, ongoing pivotal trials under an FDA investigational device exemption, and recent regulatory and intellectual property developments.
Regentis Biomaterials Ltd. (RGNT), a regenerative medicine company developing the GelrinC hydrogel implant for knee cartilage repair, reported first-half 2026 results and a business update. The pivotal U.S./EU GelrinC trial has enrolled 47 of 80 planned patients, with 43 completing two-year follow-up, and enrollment is now expected to finish around year-end 2026. GelrinC holds a CE Mark in Europe and is being prepared for commercialization through surgeon training and Centers of Excellence. Regentis strengthened its capital position via a June 2026 private placement raising approximately $6.5 million gross and repaid $1.2 million of short‑term shareholder and insider loans, ending June 30, 2026 with $9.0 million of cash and cash equivalents and shareholders’ equity of $7.7 million. For the six months, the company recorded a net loss of $2.6 million, driven by higher research and development and public-company general and administrative costs. Management expects existing cash to fund operations through September 2027, but the company discloses substantial doubt about its ability to continue as a going concern because it remains pre‑revenue, accumulates losses and may not secure additional financing on acceptable terms.
Regentis Biomaterials Ltd. received a Schedule 13G from Rosalind Advisors Inc., Rosalind Master Fund L.P., Steven Salamon and Gilad Aharon regarding their beneficial ownership of its common shares. The group reports up to 1,428,570 securities tied to Regentis, consisting of 701,685 common shares and 726,885 shares issuable upon exercise of warrants. The reported positions are calculated against 7,023,921 ordinary shares outstanding as of July 8, 2026. The filing notes “blocker” provisions, so the actual number of shares beneficially owned is lower than the full convertible and exercisable amount. Rosalind Advisors and Mr. Salamon may be deemed beneficial owners through their advisory roles but explicitly disclaim beneficial ownership of the shares.
Regentis Biomaterials reports that the Japan Patent Office issued a Notice of Allowance for a patent covering its organic solvent-free manufacturing process and ready-to-use liquid formulation used in GelrinC, its regenerative treatment for focal articular knee cartilage injuries, strengthening intellectual property protection in a key orthopedic market.
The patented technology is designed to eliminate organic solvents and deliver a stable, ready-to-use liquid, with stated manufacturing advantages including a 5x increase in yield, simplified production, improved environmental profile, and scalability. GelrinC has CE Mark approval in Europe, is over 50% enrolled in a pivotal U.S. FDA study, and targets sizable opportunities including an estimated 470,000 annual U.S. cartilage knee repair cases and a Japanese cartilage repair market projected at nearly $289 million by 2030.
Regentis Biomaterials Ltd. received approval from a European Notified Body to manufacture GelrinC using a new solvent-free process that increases production yield by approximately 400% and delivers five times more product from the same volume ahead of its European commercial launch.
The next-generation process lowers manufacturing costs, improves occupational and environmental safety, and is designed for scalable commercial production, with clinical testing validating consistent product quality and clinical performance. GelrinC is an off-the-shelf, cell-free hydrogel implant for focal knee cartilage repair, performed in a single 10-minute procedure and positioned as an alternative to microfracture and complex cell-based therapies in a U.S. market valued at $3 billion. GelrinC already holds CE Mark approval in Europe and is being introduced through Centers of Excellence and surgeon training programs, while a pivotal FDA study in the United States has completed over 50% enrollment to support potential future regulatory clearance.
Regentis Biomaterials Ltd. granted Director Susan Alpert an employee stock option for 24,826 Ordinary Shares at an exercise price of $2.16 per share. The grant, approved by the board on June 4, 2026 and subject to shareholder approval, became effective after shareholders approved it on July 9, 2026. The options vest in twelve quarterly installments starting September 4, 2026 and continue through June 4, 2029, and expire on June 4, 2036. Following this grant, Alpert holds options for 24,826 shares directly.
Regentis Biomaterials Ltd. is registering for resale by existing investors up to 3,807,143 Ordinary Shares. This includes 1,844,543 shares sold in a June 2026 private placement plus shares issuable upon exercise of Pre-Funded, Ordinary and Placement Agent Warrants. Ordinary Shares outstanding were 7,023,921 as of July 13, 2026; this is a baseline figure, not the amount being offered.
Regentis will not receive proceeds from selling shareholders’ resales. It may receive approximately $8.21 million only if all Offered Warrants are exercised for cash. Regentis is a regenerative medicine company developing GelrinC, an off-the-shelf hydrogel implant for articular knee cartilage injuries, currently in a pivotal trial in the United States and Europe.
Regentis Biomaterials director Ben-Elazar Pini received two employee stock option grants covering 8,313 and 24,826 ordinary shares. The options have exercise prices of 0.0030 and 2.1600 per share; one grant is fully vested, while the other vests quarterly through June 4, 2029 under the 2024 Share Option Plan.
Valentine Keith reported acquisition or exercise transactions in this Form 4 filing.
Regentis Biomaterials Ltd. director Keith Valentine received a grant of 24,826 employee stock options to buy ordinary shares at $2.16 per share. The grant was approved by the board on May 28, 2026, subject to shareholder approval obtained July 9, 2026. The options vest in 12 quarterly installments starting August 28, 2026 and fully vest on May 28, 2029, and expire on May 28, 2036. Following this grant, Valentine holds options for 24,826 shares from this award.